Table 4 Characteristics of patients by cholecystitis-related complications
Characteristic | Complications (n = 6) | No complications (n = 19) |
|---|---|---|
ICI type, n (%) | ||
Anti–CTLA-4 | 1 (17) | 7 (37) |
Anti–PD-1/L1 | 3 (50) | 12 (63) |
Combination | 2 (33) | 0 (0) |
Months from ICI to onset, median (IQR) | 7 (1–10) | 5 (0.1–31) |
Positive infectious workup, n (%) | 2 (33) | 0 (0) |
Peak biochemistry values, median (IQR) | ||
White blood cell count, cells/L | 11 (5–16) | 6 (1–33) |
Total bilirubin, mg/dL | 1.5 (0.7–3.9) | 1.3 (0.4–36.1) |
Direct bilirubin, mg/dL | 0.9 (0.2–3.5) | 1.1 (0.2–33.4) |
Alkaline phosphatase, IU/L | 169 (34–579) | 167 (61–1281) |
ALT, IU/L | 39 (19–364) | 62 (12–296) |
Hospitalization, n (%) | 5 (83) | 10 (53) |
Intravenous fluid, n (%) | 6 (100) | 11 (58) |
Antibiotics, n (%) | 6 (100) | 12 (63) |
Surgical treatment, n (%) | 5 (83) | 6 (32) |
Duration of symptoms in days, median (IQR) | 9 (5–17) | 4 (1–14) |
Restarted ICI therapy, n (%) | 2 (33) | 8 (42) |